Get the Stockscreener App
16.26
0.06%
0.01
Pharming Group N V Adr stock is traded at $16.26, with a volume of 15,247.
It is up +0.06% in the last 24 hours and up +19.82% over the past month.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
See More
Previous Close:
$16.25
Open:
$16.37
24h Volume:
15,247
Relative Volume:
1.02
Market Cap:
$1.11B
Revenue:
$277.56M
Net Income/Loss:
$-13.33M
P/E Ratio:
-85.58
EPS:
-0.19
Net Cash Flow:
$-6.54M
1W Performance:
-3.27%
1M Performance:
+19.82%
6M Performance:
+55.00%
1Y Performance:
+109.54%
1-Day Range:
$16.25
$16.64
1-Week Range:
$15.81
$17.13
52-Week Range:
$7.35
$17.76
Pharming Group N V Adr Stock (PHAR) Company Profile
Compare PHAR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHAR
Pharming Group N V Adr
|
16.26 | 1.11B | 277.56M | -13.33M | -6.54M | -0.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pharming Group N V Adr Stock (PHAR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | Jefferies | Buy |
Pharming Group N V Adr Stock (PHAR) Latest News
Earnings Estimates Moving Higher for Pharming Group (PHAR): Time to Buy? - MSN
Does Pharming Group (PHAR) Have the Potential to Rally 100.91% as Wall Street Analysts Expect? - sharewise.com
FY2025 EPS Estimates for Pharming Group Raised by Analyst - Defense World
Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase After Better-Than-Expected Earnings - Defense World
Pharming Group (NASDAQ:PHAR) Shares Gap Up After Better-Than-Expected Earnings - Defense World
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update - MarketBeat
Pharming Group (PHAR) to Release Earnings on Thursday - Defense World
Pharming Group (NASDAQ:PHAR) Upgraded at Weiss Ratings - Defense World
Pharming Group (NASDAQ:PHAR) Shares Gap DownHere's Why - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Up 9.5%What's Next? - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Down 71.8% in September - MarketBeat
Pharming Group (NASDAQ:PHAR) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Short Interest in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Increases By 64.2% - MarketBeat
Pharming Group (NASDAQ:PHAR) Stock Price Down 4.6%What's Next? - MarketBeat
Pharming Group (NASDAQ:PHAR) Stock Price Up 7%Still a Buy? - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Gap UpTime to Buy? - MarketBeat
Pharming Group (NASDAQ:PHAR) Sees Large Volume IncreaseTime to Buy? - MarketBeat
QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study - Finviz
Pharming Group (NASDAQ:PHAR) Shares Gap Up – Still a Buy? - Defense World
Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Pharming Group (NASDAQ:PHAR) Stock Price Down 4.4%What's Next? - MarketBeat
Short Interest in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Increases By 378.6% - MarketBeat
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal - The Globe and Mail
Pharming Group (NASDAQ:PHAR) Stock Price Up 5%Here's Why - MarketBeat
Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus - Zacks Investment Research
Pharming Group appoints Kenneth Lynard as Chief Financial Officer - GlobeNewswire Inc.
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin - The Globe and Mail
Pharming Group (NASDAQ:PHAR) Shares Gap Up – Should You Buy? - Defense World
Wall Street Analysts See a 142.26% Upside in Pharming Group (PHAR): Can the Stock Really Move This High? - ca.finance.yahoo.com
Wall Street Analysts Think Pharming Group (PHAR) Could Surge 145.75%: Read This Before Placing a Bet - Yahoo Finance
Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume on Earnings Beat - Defense World
New Strong Buy Stocks for August 1st - TradingView
Pharming Group (NASDAQ:PHAR) Shares Gap Up After Earnings Beat - Defense World
Best Momentum Stocks to Buy for July 25th - TradingView
New Strong Buy Stocks for July 25th - TradingView
New Strong Buy Stocks for July 17th - MSN
Best Momentum Stocks to Buy for July 17th - NewsBreak: Local News & Alerts
PHAR stock hits 52-week high at $11.14 amid robust growth By Investing.com - Investing.com South Africa
Pharming Group N V Adr Stock (PHAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):